தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் கீழ் ஒப்பந்த இல்லை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் கீழ் ஒப்பந்த இல்லை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் கீழ் ஒப்பந்த இல்லை Today - Breaking & Trending Today

Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured .
LuminosticsFebruary 16, 2021 GMT
Luminostics’s Clip COVID Rapid Antigen Test uses a smartphone-based analyzer to obtain results in 30 minutes from nasal swabs in decentralized settings
Clip COVID’s emergency use authorization (EUA) in December 2020 closely followed the award of a $26.1 million contract to Luminostics by the National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA)
Luminostics is quickly ramping up production with a target capacity of 4,000,000+ tests per month by summer 2021
The company will soon seek EUA from the FDA for non-prescription, non-laboratory use of the Clip COVID Rapid Antigen Test ....

United States , Services Emergency Fund , Emory University , Human Services , National Institutes Of Health , Biomedical Advanced Research , Drug Administration , Development Authority , National Institute Of Biomedical Imaging , Public Health , Department Of Health , Office Of The , National Institutes Of Health Under Contract No , Antigen Test , National Institutes , Northern California , Rapid Acceleration , National Institute , Biomedical Imaging , Social Services Emergency Fund , Assistant Secretary , Corporate News , Products And Services , Covid 19 Pandemic , Lung Disease , Coronavirus Pandemic ,

Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the .
Meridian Bioscience Inc.February 3, 2021 GMT
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company’s SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio.
The funding will help Meridian expand production of Revogene® test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near the corporate headquarters in the Village of Newtown (Cincinnati, OH). The expansion will be ....

Village Of Newtown , United States , Franciss Collins , Tony Serafini Lamanna , Charlie Wood , Mark Kobasuk , Regional Growth Partnership , Services Emergency Fund , National Institute Of Health , Radx Advanced Technology Platforms , Department Of Defense , National Institute Of Biomedical Imaging , Public Health , Jobsohio Economic Development Grant , Department Of Health , National Institutes Of Health Under Contract No , Radx Initiative , Biomedical Advanced Research , National Institutes Of Health , Human Services , Us Department Of Health , Drug Administration , Development Authority , Ohio Southeast Economic Development , Technology Research Network , Meridian Bioscience Inc ,

Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown

Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown
February 03, 2021 10:30 ET
| Source:
Meridian Bioscience Inc.
Meridian Bioscience Inc.
Cincinnati, Ohio, UNITED STATES
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company s SARS-CoV-2 molecular diagnostic test on its Revogene
® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx
SM) initiative and an additional grant from JobsOhio.
The funding will help Meridian expand production of Revogene ....

Village Of Newtown , United States , Franciss Collins , Tony Serafini Lamanna , Charlie Wood , Mark Kobasuk , Regional Growth Partnership , Services Emergency Fund , National Institute Of Health , Radx Advanced Technology Platforms , Department Of Defense , National Institute Of Biomedical Imaging , Public Health , Jobsohio Economic Development Grant , Department Of Health , National Institutes Of Health Under Contract No , Radx Initiative , Biomedical Advanced Research , National Institutes Of Health , Human Services , Us Department Of Health , Drug Administration , Development Authority , Ohio Southeast Economic Development , Technology Research Network , Meridian Bioscience Inc ,